On July 11th, Glonui reported that Simcere Pharma (02096.HK) issued an announcement that on July 8th, 2024, the group's innovative drug Xinnuoxin (Xinnuoteweipian/ritonavir combination package) passed the NMPA review and approval with conditions and was approved for conventional approval, and its indication is for the treatment of adult patients with mild to moderate COVID-19. Xinnuoxin became the first orally administered anti-COVID-19 drug in China to receive conventional approval.
先声药业(02096.HK)：抗新冠创新药先诺欣获得国家药监局常规批准
Simcere Pharma (02096.HK): Innovative drug Xinnuoxin for COVID-19 has received regular approval from the National Medical Products Administration.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.